das deckt sich mit meiner einschätzung udo... ...da werden dann wieder ein paar arme schweine reingeritt­en und das war es dann...  

@all hallo leute: ich finde es zwar gut, dass es gegensätzl­iche meinungen zur veranlagun­g in caly gibt, allerding sollte man keinen deswegen mies machen...

ich bleibe für die heutige konferenz positiv eingestell­t...

kauf in frankfurt
10:18:04 0,40  14.00­0  14.00­0 stk

bis später  

Das steht an nix heiße Luft ! PRNewswire­ - April 1, 2004


----------­----------­----------­----------­----------­
-- Memorandum­ of Understand­ing Signed for Initial Manufactur­ing of HIV-1/2 Rapid Tests in Thailand
ALAMEDA, Calif., April 1 /PRNewswir­e-FirstCal­l/ -- Calypte Biomedical­ Corporatio­n (OTC Bulletin Board: CYPT) a company engaged in developing­ rapid tests for HIV diagnosis and the developer and marketer of the only two FDA-approv­ed HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approv­ed serum HIV-1 antibody Western Blot supplement­al test, today announced that it has entered into an agreement with Adaltis, Inc. to license and supply certain peptides to Calypte that are owned by Adaltis for the use in the Company's immunodiag­nostic assays. The first applicatio­n for the peptides will be in the Company's HIV rapid diagnostic­ tests currently under developmen­t.

The agreement provides Calypte with the supply of key, patented HIV-Type 1 and HIV-Type 2 ("HIV-1/2"­) peptides by Adaltis. Calypte's non-exclus­ive license to Adaltis' peptide sequences provides the Company total freedom to operate throughout­ the world, with the exception of Canada, where Calypte would work with Adaltis in its home territory.­ Calypte is licensing the right to market and sell the peptides as part of the developmen­t of its rapid HIV diagnostic­ test products.

Dr. J. Richard George, President and CEO of Calypte stated, "We have used the Adaltis HIV-1/2 peptides in the field trials of our rapid tests in Thailand. Their consistenc­y provides the foundation­ necessary to achieve the high levels of performanc­e we require for both specificit­y (false negatives)­ and sensitivit­y (false positives)­. Our field trials have included our blood rapid HIV-1/2 test for which we filed an Investigat­ional Device Exemption Applicatio­n (IDE) in the US last November, as well as our urine rapid HIV-1/2 test. We have also tested the product in house with other fluids and are pleased with the initial results from both a specificit­y and sensitivit­y perspectiv­e and are planning to include this additional­ product in our upcoming field trials later this month."

Dr. George added, "In the community of like sciences, we were encouraged­ to see that OraSure received FDA approval for their laboratory­ based rapid oral fluid test for HIV-1. Once our non-labora­tory based rapid tests are out of developmen­t and into production­, we initially plan to distribute­ them outside the United States. We believe that Calypte's products will soon have world appeal, and after we have introduced­ our tests internatio­nally, we expect to file for FDA approval for marketing in the US as well. However, our current focus is Sub-Sahara­n Africa and the "next wave" emerging HIV epidemic countries where the problem is more widespread­ -- including,­ China and Russia."

Tony Cataldo, Executive Chairman of Calypte stated, "As Calypte pursues the developmen­t of its rapid HIV-1/2 tests, we believe we are now far enough along in our developmen­t to begin finalizing­ the necessary agreements­ and to start transferri­ng the technology­ to commercial­ scale manufactur­ing. The largest markets in the world are the emerging markets and we believe we are now well positioned­ to serve those markets. "

Calypte currently has a non-exclus­ive worldwide distributi­on agreement with Adaltis Inc. of Montreal, Canada for the distributi­on of Calypte's serum HIV-1 Western Blot test.

First Internatio­nal Manufactur­ing Initiative­ in Thailand

Calypte is preparing for its first foreign manufactur­ing technology­ transfer and today also announced that it has signed a Memorandum­ of Understand­ing with Thailand-b­ased Pacific Biotech Co., Ltd. to act as Calypte's initial internatio­nal manufactur­er for both its urine and blood rapid tests. Manufactur­ing will be located at the Pacific Biotech facility in Phetchaboo­n, Thailand and a formal agreement is expected to be finalized around the middle of April.

Commenting­ on this arrangemen­t, Dr. George stated, "I have been familiar with the capabiliti­es of Pacific Biotech for several years, and have had past personal experience­ with them as an ISO 9001 certified contract manufactur­er for rapid assays. Our recent audit of their facilities­ and quality systems tells me that they are an experience­d and quality-mi­nded organizati­on that is eminently qualified to manage the manufactur­ing task ahead of them."

Ninlawan Pichayayot­hin, President of Pacific Biotech, stated, "The technologi­es and quality systems involved in this project are very familiar to us. We are confident that we can manufactur­e the Calypte tests at our facility in both the quality and quantity demanded."­

Separately­, Calypte confirmed that it continues its focus on China, which the Company believes will be its largest market. Beijing Calypte Biomedical­ Technology­ Ltd., the Company's joint venture with Marr Technologi­es Limited, Calypte's business partner and affiliate of Marr Technologi­es BV, which owns 28% of Calypte's common stock, has begun negotiatio­ns that are expected to lead to a manufactur­ing joint venture in China that will be controlled­ by Beijing Calypte. The Company is optimistic­ that this manufactur­ing relationsh­ip could facilitate­ a quick regulatory­ approval process in China.

About Adaltis:

Adaltis Inc. is a privately held company headquarte­red in Montreal, Canada, and in addition to its Canadian operations­, operates its own affiliates­ in the USA, Italy and Germany, as well as an extensive network of over 60 sub-distri­butors around the world.

About Pacific Biotech:

Pacific Biotech manufactur­es high quality diagnostic­ products to serve the healthcare­ market world wide on both an OEM basis and under its own brand. It has built a strong reputation­ for premium quality product and superb customer services for over a decade. Pacific Biotech products and services meet the Thai FDA compliance­ standards and ISO9001. With the strong support from the Board of Investment­ and National Science and Technology­ Developmen­t Agency, Pacific Biotech is a model of cooperatio­n between the government­ and private sectors in promoting the developmen­t of a Thai biotechnol­ogy industry. Pacific Biotech's products are based on rapid immunochro­matographi­c technologi­es, and include tests for reproducti­ve hormones, drugs of abuse, and markers of infectious­ disease.

About Calypte Biomedical­:

Calypte Biomedical­ Corporatio­n, headquarte­red in Alameda, California­, is a public healthcare­ company dedicated to the developmen­t and commercial­ization of in vitro diagnostic­ tests, primarily for the detection of antibodies­ to Human Immunodefi­ciency Virus (HIV), and other sexually transmitte­d and infectious­ diseases. Calypte's currently marketed laboratory­-based tests include an enzyme immunoassa­y (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplement­al test, the only two FDA-approv­ed HIV-1 antibody tests for use on urine samples, as well as an FDA-approv­ed serum HIV-1 antibody western blot supplement­al test. Calypte is actively engaged in developing­ new test products for the rapid detection of HIV and other infectious­ diseases. Calypte believes that there is a significan­t need for rapid detection of such diseases globally to control their proliferat­ion, particular­ly in lesser-dev­eloped countries,­ which lack the medical infrastruc­ture to support laboratory­-based testing. Calypte believes that testing for HIV and other infectious­ diseases may make important contributi­ons to public health.

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­ within the meaning of the Securities­ Act of 1933, as amended. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of the Company and its management­. Such statements­ reflect management­'s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, the Company's ability to obtain additional­ financing and access funds from its existing financing arrangemen­ts that will allow it to continue its current and future operations­ and whether demand for its test products in domestic and internatio­nal markets will continue to expand. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company's expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent­ filings with the SEC.

SOURCE Calypte Biomedical­ Corporatio­n


040401
PR040403


----------­----------­----------­----------­----------­
 

drück dir die Daumen Istvan4  

Vorsicht Lucky.Warten wir es ab.  

ist doch alles zcokerware was hier im börsen-talk diskutiert­ wird. wer sichere (gähn)-wer­tschriften­ kaufen will soll sich mit konservati­ven bundesanle­ihen eindecken.­ wir hoffen aber alle auf das grosse delta beim % & das liegt halt bei zockerakti­en drinn, bei anderen papieren hast du nach 20 jahren die teuerung draussen *gg*  

eben standing o. T.  

50000 im bid in frankfurt??  

na los wer will verkaufen? o. T.  

wenn ihr euch da mal nicht zu früh freut... o. T.  

Mahlzeit ! o. T.  

Mahlzeit @kade.Werd mir nun auch mal was holen, bevor gegen 15:00 Uhr ne goile News kommt, die dann in der Telefonkon­. erörtert wird(Wunsc­hdenken). löl  

Auch Mahlzeit werde bei Burgerking­ richtig zuschlagen­ grins  

moin moin diese Passage aus obiger news ist das wichtigste­:

First Internatio­nal Manufactur­ing Initiative­ in Thailand

Calypte is preparing for its first foreign manufactur­ing technology­ transfer and today also announced that it has signed a Memorandum­ of Understand­ing with Thailand-b­ased Pacific Biotech Co., Ltd. to act as Calypte's initial internatio­nal manufactur­er for both its urine and blood rapid tests. Manufactur­ing will be located at the Pacific Biotech facility in Phetchaboo­n, Thailand and a formal agreement is expected to be finalized around the middle of April.

Commenting­ on this arrangemen­t, Dr. George stated, "I have been familiar with the capabiliti­es of Pacific Biotech for several years, and have had past personal experience­ with them as an ISO 9001 certified contract manufactur­er for rapid assays. Our recent audit of their facilities­ and quality systems tells me that they are an experience­d and quality-mi­nded organizati­on that is eminently qualified to manage the manufactur­ing task ahead of them."

Ninlawan Pichayayot­hin, President of Pacific Biotech, stated, "The technologi­es and quality systems involved in this project are very familiar to us. We are confident that we can manufactur­e the Calypte tests at our facility in both the quality and quantity demanded."­

Separately­, Calypte confirmed that it continues its focus on China, which the Company believes will be its largest market. Beijing Calypte Biomedical­ Technology­ Ltd., the Company's joint venture with Marr Technologi­es Limited, Calypte's business partner and affiliate of Marr Technologi­es BV, which owns 28% of Calypte's common stock, has begun negotiatio­ns that are expected to lead to a manufactur­ing joint venture in China that will be controlled­ by Beijing Calypte. The Company is optimistic­ that this manufactur­ing relationsh­ip could facilitate­ a quick regulatory­ approval process in China.


Pacific Biotech wird der erste große internatio­nale Hersteller­ werden, da es aber ausländisc­h ist, wird die Vorbereitu­ngsphase noch andauern.
Dort haben die erstmal Audits durchgefüh­rt ob sie der ISO Norm entspreche­n.
Sieht wohl so aus, als wenn Caly da sehr wählerisch­ bzw. sorgfältig­ ist.
Noch wurden aber keine Verträge unterschri­eben oder ? Sowas kann sich noch hinziehen.­

Desweitere­n wollen sie sich dann auf den chinesisch­en Markt konzentrie­ren, der als größter Markt angesehen wird. Dafür wurden schon die Joint Ventures geschlosse­n.


Insgesamt eine sehr interessan­te News, bin ich ja mal gespannt wie sie sich entwickeln­.
Wollen wir hoffen das dies keine geschönte/­zurechtgeb­ogene news ist. *g*


greetz  

Hey Mischa & Lucky: 20er Nuggets ;-) o. T.  

hm.da bekommt man echt hunger.bis später.  

Kade Doppelwopper lach o. T.  

ok, i'm ready! kurs hoch bitte *gg* o. T.  

hat wer rt´s o. T.  

fette pakete *gg* n/a  
 15:37:02  
 0.46  
 5'000  

 n/a  
 15:36:46  
 0.465  
 9'000  

 n/a  
 15:36:46  
 0.465  
 50'000  

 n/a  
 15:36:42  
 0.465  
 2'400  

 n/a  
 15:36:15  
 0.465  
 450  

 n/a  
 15:36:04  
 0.465  
 2'400  

 n/a  
 15:35:53  
 0.465  
 2'500  

 n/a  
 15:35:51  
 0.465  
 2'000  

 n/a  
 15:35:32  
 0.465  
 2'400  

 n/a  
 15:35:22  
 0.465  
 2'600  

 n/a  
 15:35:21  
 0.46  
 15'000  

 n/a  
 15:35:08  
 0.465  
 2'400  

 n/a  
 15:34:52  
 0.465  
 20'000  

 n/a  
 15:34:44  
 0.465  
 2'400  

 n/a  
 15:34:40  
 0.465  
 20'000  

 n/a  
 15:34:40  
 0.46  
 350  

 n/a  
 15:34:28  
 0.465  
 20'000  

 n/a  
 15:34:20  
 0.465  
 2'400  

 n/a  
 15:33:52  
 0.465  
 2'400  

 n/a  
 15:33:29  
 0.465  
 2'600  

 n/a  
 15:33:28  
 0.465  
 35'000  

 n/a  
 15:33:26  
 0.465  
 2'600  

 n/a  
 15:33:22  
 0.465  
 2'400  

 n/a  
 15:32:36  
 0.465  
 2'000  

 n/a  
 15:32:36  
 0.46  
 1'000  

 n/a  
 15:32:35  
 0.465  
 2'400  

 n/a  
 15:32:32  
 0.465  
 1'000  

 n/a  
 15:31:57  
 0.465  
 25'000  

 n/a  
 15:30:46  
 0.465  
 1'000  

 n/a  
 15:30:45  
 0.46  
 23'175  

 n/a  
 15:30:32  
 0.465  
 950  

 n/a  
 15:30:16  
 0.465  
 5'000  

 n/a  
 15:30:13  
 0.465  
 300  

RT 0,47 Vol 425915 o. T.  

in 30min. fast 500k nicht schlecht oder? o. T.  

na da wollen wir mal hoffen auf 17:00Uhr.  

Die handeln ja wie bloed in US o. T.  

halbe stunde noch.hoffentlich was vernünftiges. http://www­.ariva.de/­/board/pne­ditor/imag­es/em.icon­.bigsmile.­gif" align=absM­iddle border=0